T3 is essential for normal development and metabolism. Its action is mediated by its binding to the nuclear receptors TR*α*1 and TR*β*1/2, which are ligand-dependent transcription factors encoded by the *THRA* and *THRB* genes. *THRA* germline mutations cause a rare genetic disease called RTH*α*, first reported in 2012 \[[@B1], [@B2]\]. The variety of symptoms, their variable severity, and the absence of reliable biochemical markers make the diagnosis difficult \[[@B3], [@B4]\]. Only 20 missense and frameshift mutations have been reported to date, in 31 patients ([Table 1](#T1){ref-type="table"}). From this small group of patients and analysis of animal models, researchers have determined the disease severity correlates with the inability of the receptor to release transcription corepressors in the presence of T3 \[[@B13]\]. This can result from either a decrease in the affinity of TR*α*1 for T3 or from an alteration of its C-terminal helix, which normally recruits transcription coactivators upon T3 binding, releasing corepressors.

###### 

Known *THRA* Mutations

  Position                                 DNA Mutation   Mutation Type   Amino Acid   No. of Cases   Country          Skeletal     Brain    Other Traits           First Author
  ---------------------------------------- -------------- --------------- ------------ -------------- ---------------- ------------ -------- ---------------------- ----------------------------
  207                                      Unknown        Missense        G207E        2              Belgium          Nd           Nd       Nd                     Unpublished
  211                                      632A\>G        Missense        D211G        2              Netherlands      SS, MC       ES, DM   hBMI                   van Gucht\[[@B5]\]
  263                                      788 C\>T       Missense        A263V        3              United Kingdom   BM           DM       AN, CP                 Moran \[[@B6]\]
  263                                      789 G\>T       Missense        A263S        7              Turkey           SS, MC, WB   DM       CP, AN, hBMI, ST       Demir \[[@B7]\]
  274                                      821T\>C        Missense        L274P        1              United Kingdom   SS, BM, WB   DM       AN, BF                 Moran \[[@B6]\]
  348                                      1044G\>T       Missense        A348S        1              India            Nd           ASD      Nd                     Kalikiri \[[@B8]\]
  351                                      1053C\>G       Missense        H351Q        1              India            Nd           ASD      Nd                     Kalikiri \[[@B8]\]
  359                                      1075C\>G       Missense        N359Y        1              France           SS, BM                CP, AN                 Espiard \[[@B9]\]
  367                                      1099C\>A       Missense        L367M        1              India            Nd           ASD      Nd                     Kalikiri \[[@B8]\]
  380                                      1137ins.4nt    Frameshift      C380fs387X   1              Turkey           SS, BM, MC   DM       CP, BF, AN, hBMI       Demir \[[@B7]\]
  382                                      1144G\>C       Missense        A382P        1              India            Nd           ASD      Nd                     Kalikiri \[[@B8]\]
  382                                      c1144delG      Frameshift      A382PfsX7    1              United Kingdom   SS, MC       ES, DM   CP, hBMI, ST, BF, AN   Moran \[[@B10]\]
  384                                      Unknown        Missense        R384C        1              Canada           Nd           ASD      Nd                     Yuen \[[@B11]\]
  384                                      1151 G\>A      Missense        R384H        2              Turkey           SS, MC, WB   DM       AN, CP, hBMI           Demir \[[@B7]\]
  395                                      c.1183G\>T     Nonsense        E395X        1              China            SS           DM       AN, CP                 Present study
  397[*^a^*](#t1n1){ref-type="table-fn"}   insert 1nt     Frameshift      F397fs406X   2              Greece           SS, MC       DM       AN, CP                 van Mullem \[[@B2]\]
  398                                      1193C\>G       Missense        P398R        1              Poland           SS, MC, BM   DM       AN, CP                 Tylki-Szymańska \[[@B12]\]
  401                                      1202T\>C       Missense        F401S        1              India            Nd           ASD      Nd                     Kalikiri \[[@B8]\]
  403                                      1207G\>A       Missense        E403K        2              Poland           SS, MC, BM   DM       AN, CP                 Tylki-Szymańska \[[@B12]\]
  403                                      1207G\>T       Missense        E403X        1              United Kingdom   SS, MC, WB   DM       CP, hBMI               Bochukova \[[@B1]\]
  403                                      1207G\>T       Nonsense        E403X        1              Poland           SS, MC, BM   DM       AN, CP                 Tylki-Szymańska \[[@B12]\]
  405                                      1213T\>C       Missense        F405L        1              India            Nd           ASD      Nd                     Kalikiri \[[@B8]\]

Abbreviations: AN, anemia; ASD, autism spectrum disease; BF, broad face; BM: long bones malformation, dysgenesis or hyperostosis; CP, constipation; DM, delayed milestones; ES, epileptic seizures; hBMI, high body mass index; MC, macrocephalia; Nd, not determined; SS, short stature, ST, skin tags; WB, Wormian bones.

AA 397-410 constitutes the C-terminal helix of TR*α*1.

1. Case Report {#s1}
==============

We report on a patient with RTH*α* in China. The patient is the only child of healthy, unrelated parents. This boy was born at full term by vaginal delivery. His birth weight was 4 kg. His developmental milestones were delayed: He walked at 18 months and knew only two words at age 2 years ("mama" and "baba"). Poor coordination and clumsiness were noted. At 2 years old, he underwent the Denver Developmental Screening Test, which result of which was abnormal. The child had chronic constipation.

On examination at age 2 years, the patient's height was 80 cm (reference range, 82.1 to 95.3 cm). At 3 years, his skeletal growth remained retarded (83.5 cm; reference range, 89.7 to 104.1 cm). He was disproportionately short, with a short arm span (78 cm). The patient's heart rate was low (85/min; reference range, 100 to 120/min). His skin was thick without skin tags. The face and nasal bridge were broad, but there was no macroglossia.

The patient underwent multiple thyroid function tests ([Table 2](#T2){ref-type="table"}). Although T4 and TSH levels remained within reference ranges, his T3 level was slightly elevated. This resulted in a marked reduction of the T4-to-T3 ratio. Consistent with the patient's slow body growth, his IGF-1 level was low. Muscle creatine kinase levels were also elevated, possibly because of the elevated T3 level. The patient's Hb level was low, indicative of mild anemia. Results of the screening tests for metabolic defects, including analyses of blood and urine amino acids and urinary organic acid were normal. Routine karyotyping (G-bands) showed 46,XY.

###### 

Patient's Biochemical and Metabolic Measurements Before Treatment

  Variable   Reference Values for Children   Age (Mo)                  
  ---------- ------------------------------- ---------- ------- ------ ------
  T4         51.83--122.49 ng/mL             77.8       67.7    79.1   
  fT4        1.20--1.73 ng/dL                0.91       1.01    0.87   
  T3         0.99--2.27 pg/mL                2.18       2.25    2.30   
  fT3        2.75--4.68 pg/mL                5.23       5.28    5.25   
  TSH        0.38--7.31 μIU/mL               1.38       1.53    1.38   
  TPO Ab     0--60 IU/mL                                        47.8   
  Tg         0--35 ng/mL                                        43.6   
  TgAb       0--60 IU/mL                                        \<15   
  Hb         110--140 g/L                    86         90             87
  MCV        80--100 fL                      88         87             89
  MCH        27--34 pg                       30.2       29.6           28.8
  MCHC       320--360 g/L                    343        342            325
  CK         25--225 U/L                     981.6      404.9          
  CK-MB      0.0--3.7 ng/mL                  8.6        7.4            
  IGF-1      40--189 ng/mL                   33.7       36.3           

Abbreviations: Ab, antibody; CK, creatine kinase; CK-MB, creatine kinase-muscle/brain; fT3, free T3; fT4, free T4;MCH, mean corpuscular Hb; MCHC, mean corpuscular Hb concentration; MCV, mean corpuscular volume; Tg, thyroglobulin; TgAB, thyroglobulin antibody; TPO, thyroid peroxidase.

We evaluated the thyroid gland function by measuring serum thyroglobulin level, which was slightly elevated. We searched for antibodies directed against thyroid peroxidase, or thyroglobulin, which were absent at this early stage. Observations on ultrasonic cardiogram and thyroid pelvic ultrasound were normal. Head and pituitary MRI appeared normal. Overall, the function of the pituitary--thyroid gland axis appeared close to normal, in contrast with the severe symptoms evocative of hypothyroidism. Radiographic studies showed a normal morphology of the vertebral column and no sign of hip dislocation. Wormian bones were absent. At 3 years old, the patient's head circumference was within normal range (51 cm; reference range, 45.7 to 52.2 cm). After obtaining the patient's informed consent (2016034), we performed DNA sequencing using target region sequencing and Sanger sequencing. This revealed that the patient was heterozygous for a *THRA* mutation (c.1183G\>T,p.E395X), which was absent in his parents.

The initial dose of 25 μg/d levothyroxine was ordered. The child was irregularly taking medication. Approximately 6 months later, his motor coordination remained poor and clumsiness was visible, but his parents rejected further examination. After then, he was lost to follow-up.

2. Discussion {#s2}
=============

The E395X mutation eliminates the C-terminal helix of TR*α*1 and, thus, is expected to display consequences similar to that of C392X, F397fs406X, and E403X mutations, which exert a strong dominant-negative influence in heterozygous cells. Our observations confirm that, for this type of mutation, levothyroxine-T4 treatment provides little benefit, and the manifestations of RTH*α* are severe.

Our findings also indicate the variability in RTH*α* manifestations; RTH*α* remains difficult to recognize even in its severe form. In the patient described here, constipation, small stature, mild anemia, and mental retardation were typical traits of the disease that were reported also for the aforementioned similar cases. The T4 and TSH levels also remained within normal range, and T3 was slightly elevated, which fits the general trend of observing a low T4-to-T3 ratio in these patients. The moderate decrease in IGF-1 and the increase in muscle creatine kinase level are also consistent with previous case reports \[[@B3]\]. By contrast, the slight elevation in thyroglobulin level was not typical of the disease. Perhaps more importantly, the patient's head circumference was normal, whereas it is elevated in all patients with mutations altering the C-terminal helix 12 of the receptor ([Table 1](#T1){ref-type="table"}). Therefore, our data confirm that RTH*α* diagnosis cannot rely on a single clinical trait and that the manifestation of the disease varies even for patients with seemingly equivalent mutations.
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RTH*α*

:   resistance to thyroid hormone *α*
